• Home
  •  / Bristol-Myers Squibb

Bristol-Myers Squibb

  • Revenue$46.4 BFY, 2021
  • Market Capitalization$168.2 B2022-05-13

OverviewSuggest Edit

Bristol-Myers Squibb is a company focused that provides biopharmaceutical products. It focuses on discovering, developing, and delivering transformational medicines for patients facing diseases such as oncology (both solid tumors and hematology), immunology, cardiovascular, and fibrosis.
TypePublic
Founded1887
HQNew York, NY, USMap
Websitebms.com
Employee Ratings3.9
Overall CultureA-More
View Jobs (2,477)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2021)32,200(+7%)
Job Openings2,477
Revenue (FY, 2021)$46.4 B(+10%)
Share Price (May 2022)$75.8
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Bristol-Myers Squibb

Giovanni Caforio

Giovanni Caforio

Chairman and Chief Executive Officer
Pamela Fisher

Pamela Fisher

Vice President, Chief Diversity and Inclusion Officer
Cari Gallman

Cari Gallman

Chief Compliance and Ethics Officer
Lou Schmukler

Lou Schmukler

President, Global Product Development & Supply
Catalina Vargas

Catalina Vargas

Chief of Staff to the Chief Executive Officer
Samit Hirawat

Samit Hirawat

Executive Vice President, Chief Medical Officer, Global Drug Development
Show more

Bristol-Myers Squibb Office Locations

Bristol-Myers Squibb has offices in New York, Atlanta, Baltimore, Cambridge and in 63 other locations
New York, NY, US (HQ)
430 E 29th St 14th Floor
Atlanta, GA, US
950 East Paces Ferry Rd NE
Baltimore, MD, US
Baltimore, MD, USA
Cambridge, MA, US
100 Binney St
Columbus, OH, US
999 Polaris Pkwy #100
Devens, MA, US
38 Jackson Rd
Show all (71)

Bristol-Myers Squibb Financials and Metrics

Bristol-Myers Squibb Revenue

Embed Graph
View revenue for all periods
Bristol-Myers Squibb's revenue was reported to be $46.39 b in FY, 2021 which is a 9.1% increase from the previous period.
USD

Revenue (FY, 2021)

46.4b

Revenue growth (FY, 2020 - FY, 2021), %

9.1%

Gross profit (FY, 2021)

36.4b

Gross profit margin (FY, 2021), %

78.6%

Net income (FY, 2021)

7.0b

Market capitalization (13-May-2022)

168.2b

Closing stock price (13-May-2022)

75.8

Cash (31-Mar-2022)

12.4b
Bristol-Myers Squibb's current market capitalization is $168.2 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

22.6b26.1b42.5b46.4b

Revenue growth, %

9%16%63%9%

Cost of goods sold

6.5b8.1b11.8b9.9b

Gross profit

16.0b18.1b30.7b36.4b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

5.9b6.3b6.0b10.8b10.1b10.5b11.1b11.7b

Cost of goods sold

1.8b2.0b1.8b3.7b2.7b2.5b2.8b2.5b

Gross profit

4.1b4.3b4.2b7.1b7.4b8.0b8.2b9.3b

Gross profit Margin, %

69%68%70%66%73%76%74%79%
show all
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

12.3b14.5b14.0b

Accounts Receivable

7.7b8.5b9.4b

Inventories

4.3b2.1b2.1b

Current Assets

29.4b30.2b33.3b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

7.3b28.4b30.5b15.8b19.9b19.4b11.0b11.0b13.5b12.4b

Accounts Receivable

5.7b5.7b5.5b8.3b7.9b8.1b8.7b9.0b9.2b8.5b

Inventories

1.3b1.3b1.2b2.8b2.4b1.9b2.0b2.1b2.2b2.1b

Current Assets

17.1b37.7b40.2b31.9b34.3b34.3b27.1b29.2b31.4b30.1b
show all
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

3.5b(9.0b)7.0b

Depreciation and Amortization

1.7b10.4b10.7b

Inventories

463.0m2.7b13.0m

Accounts Payable

229.0m188.0m245.0m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

1.7b3.2b4.5b(766.0m)(846.0m)1.0b2.0b3.1b4.6b1.3b

Depreciation and Amortization

170.0m339.0m510.0m2.5b5.0b7.7b2.7b5.4b8.1b2.6b

Inventories

35.0m28.0m(7.0m)1.4b2.1b2.6b106.0m111.0m141.0m1.0m

Accounts Payable

136.0m156.0m48.0m703.0m480.0m56.0m303.0m158.0m19.0m23.0m
show all
USDFY, 2018

Revenue/Employee

968.3k
Show all financial metrics

Bristol-Myers Squibb Operating Metrics

FY, 2018FY, 2019FY, 2020

Manufacturing Facilities

777

Phase I Trials Products (Hematology)

1423

Phase II Trials Products (Hematology)

88

Research and Development Centers

71212

Bristol-Myers Squibb Acquisitions / Subsidiaries

Company NameDateDeal Size
MyoKardiaOctober 05, 2020$13.1 b
ForbiusAugust 24, 2020
CelgeneJanuary 03, 2019$74 b
IFM TherapeuticsAugust 03, 2017
Cormorant PharmaceuticalsJuly 05, 2016
Padlock TherapeuticsMarch 23, 2016$600 m
Cardioxyl PharmaceuticalsNovember 02, 2015$2 b
Flexus BiosciencesFebruary 23, 2015$1.25 b
Galecto BiotechNovember 03, 2014$444 m
F-star AlphaOctober 28, 2014$475 m
Show more

Bristol-Myers Squibb Revenue Breakdown

Embed Graph

Bristol-Myers Squibb revenue breakdown by business segment: 27.6% from Revlimid, 16.2% from Opdivo, 7.1% from Orencia, 23.2% from Eliquis, 7.2% from Pomalyst/Imnovid and 18.6% from Other

Bristol-Myers Squibb revenue breakdown by geographic segment: 63.0% from United States, 23.0% from Europe, 12.1% from Rest of World and 1.8% from Other

Human Capital Metrics

Source: www.bms.com
Embed Graph

Bristol-Myers Squibb Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

Learn more about our premium products
SecurityScorecard logo

Bristol-Myers Squibb Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

Learn more about our premium products
CSRHub logo

Bristol-Myers Squibb Online and Social Media Presence

Bristol-Myers Squibb's Trends

Embed Graph

Bristol-Myers Squibb Company Culture

  • Overall Culture

    A-

    75/100

  • CEO Rating

    A+

    80/100

  • Compensation

    A+

    85/100

  • Diversity

    A

    78/100

Learn more on Comparably

Bristol-Myers Squibb News and Updates

May 11, 2022

Lifshitz Law PLLC. Announces Investigations of AppHarvest, Inc. (NASDAQGS: APPH), Bristol-Myers Squibb Company (NYSE: BMY), InnovAge Holding Inc. (NASDAQGS: INNV), Meta Platforms, Inc. f/k/a Facebook, Inc. (NASDAQGS: FB)

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) -- AppHarvest, Inc. (NASDAQGS: APPH)
April 29, 2022

Thinking about trading options or stock in Intel Corp, Bristol-Myers Squibb, AbbVie, Teladoc Health, or Roku?

NEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTC, BMY, ABBV, TDOC, and ROKU. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
March 31, 2022

Thinking about trading options or stock in Bristol-Myers Squibb, Alibaba, Walt Disney, Meta Platforms, or Coinbase Global?

NEW YORK, March 31, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, BABA, DIS, FB, and COIN. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
December 31, 2021

China Dasatinib Market Report 2021-2025 Featuring Chia Tai Tianqing Pharmaceutical Group & Bristol-Myers Squibb Pharma EEIG

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Dasatinib Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of …
December 24, 2021

Global Infectious Disease Treatments Market Report 2021, Featuring Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis and Roche

Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Infectious Disease Treatments" report has been added to ResearchAndMarkets.com's offering.
December 23, 2021

Lifshitz Law Firm, P.C. Announces Investigations of Bristol-Myers Squibb Company (NYSE: BMY), Eargo, Inc. (NASDAQGS: EAR), Hyzon Motors Inc. (NASDAQ: HYZN), Nano-X Imaging Ltd. (NASDAQ: NNOX), and View, Inc. (NASDAQGM: VIEW)

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE: BMY)
Show more

 Bristol-Myers Squibb Frequently Asked Questions

  • When was Bristol-Myers Squibb founded?

    Bristol-Myers Squibb was founded in 1887.

  • Who are Bristol-Myers Squibb key executives?

    Bristol-Myers Squibb's key executives are Giovanni Caforio, Pamela Fisher and Cari Gallman.

  • How many employees does Bristol-Myers Squibb have?

    Bristol-Myers Squibb has 32,200 employees.

  • What is Bristol-Myers Squibb revenue?

    Latest Bristol-Myers Squibb annual revenue is $46.4 b.

  • What is Bristol-Myers Squibb revenue per employee?

    Latest Bristol-Myers Squibb revenue per employee is $1.4 m.

  • Who are Bristol-Myers Squibb competitors?

    Competitors of Bristol-Myers Squibb include Daiichi Sankyo, Regeneron Pharmaceuticals and Gilead Sciences.

  • Where is Bristol-Myers Squibb headquarters?

    Bristol-Myers Squibb headquarters is located at 430 E 29th St 14th Floor, New York.

  • Where are Bristol-Myers Squibb offices?

    Bristol-Myers Squibb has offices in New York, Atlanta, Baltimore, Cambridge and in 63 other locations.

  • How many offices does Bristol-Myers Squibb have?

    Bristol-Myers Squibb has 71 offices.